微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 57.02% | 2.96% | 0.23% | 57/159 | -2.82% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 56.89% | 0.05% | -5.6% | 59/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 60.27% | -1.5% | 4.93% | 49/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 57.44% | -6.33% | 3.71% | 58/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 55.38% | -7.97% | -2.6% | 64/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 56.86% | -10.95% | -7.06% | 63/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 61.18% | -10.78% | -0.22% | 47/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 61.32% | -0.02% | 1.9% | 49/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 60.18% | 4.71% | -5.76% | 54/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 63.86% | 10.45% | -6.88% | 47/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 68.58% | 12.54% | 11.81% | 37/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 61.33% | 8.09% | 6.72% | 55/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 57.47% | 2.15% | -0.59% | 64/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 57.81% | -2.97% | -5.13% | 65/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 60.94% | -7.12% | 7.39% | 53/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 56.74% | 5.29% | 0.86% | 69/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 56.26% | 2.72% | -5.58% | 63/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 59.58% | 8.22% | -9.19% | 59/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 65.61% | 7.14% | 21.74% | 36/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 53.89% | -16.39% | -1.6% | 74/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 54.77% | -12.18% | -0.52% | 62/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 55.05% | -12.12% | -10.1% | 64/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 61.24% | -6.92% | -4.99% | 44/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 64.46% | -2.24% | 3.35% | 45/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 62.37% | 0.26% | -0.45% | 40/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 62.65% | 0.24% | -4.77% | 44/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 65.79% | -5% | -0.22% | 28/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 65.93% | 3.08% | 5.99% | 41/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 62.2% | 14.74% | -0.47% | 38/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 62.5% | 33.06% | -9.75% | 38/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 69.25% | 151.89% | 8.26% | 21/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 63.96% | 84.71% | 17.98% | 35/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 54.21% | 57.13% | 15.42% | 41/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 46.97% | 36.53% | 70.86% | 51/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 27.49% | -10.02% | -20.61% | 68/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 34.63% | -11.97% | 0.37% | 79/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 34.5% | -11.26% | 0.29% | 55/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 34.4% | -15.37% | 12.61% | 63/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 30.55% | -25.72% | -22.33% | 57/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 39.34% | -0.4% | 1.17% | 59/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 38.88% | 2% | -4.37% | 45/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 40.65% | 2% | -1.15% | 45/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 41.13% | 4.19% | 4.14% | 41/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |